alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Research

27,780 Alzheimer's and dementia studies in plain English, each scored out of 100.

Find studies

Showing 1–25 of 160 studies in Disease mechanisms published 2025 (page 1 of 7) · 27,780 in the whole library · How the 0–100 score works

Download bibliography of these 160 studies, in this order: BibTeX (.bib) · RIS (.ris)

Browse by subject, author or institution

Each number is how many studies that link shows, with your other filters kept.

Other subjects

Authors

Names as each record prints them; the same person can appear under two spellings.

Institutions

From OpenAlex; 13,259 studies have no institution on record and are not counted here.

What “Disease mechanisms” covers

Disease mechanisms — Cell- and molecule-level research into what actually goes wrong in Alzheimer's and related diseases.

A note on reading research. One study is rarely the final word.

We try to note the size of a study, whether it was in humans or animals, and how early-stage the finding is. If a summary here doesn't make that clear, treat it with extra caution and check the original source.

Plasma MTBR-tau243 biomarker identifies tau tangle pathology in Alzheimer’s disease

✓ Peer-reviewed alzhub usefulness score 67 out of 100. Nature Medicine 2025-03-31

Insoluble tau aggregates within neurofibrillary tangles are a defining neuropathological feature of Alzheimer’s disease (AD) and closely correlate with clinical symptoms. 2 key findings →

Participants: 108 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Gut Microbiome Alterations in Mild Cognitive Impairment: Findings from the ALBION Greek Cohort

✓ Peer-reviewed alzhub usefulness score 66 out of 100. Microorganisms 2025-09-10

Emerging evidence suggests a potential role of gut dysbiosis in neurodegenerative disorders and, in particular, Alzheimer's disease (AD) pathology and cognitive decline. 4 key findings →

Design: cross-sectional Participants: 49 Evidence: moderate

Full summary, score breakdown and related studies → Original source

Choroid plexus free‐water correlates with glymphatic function in Alzheimer's disease

✓ Peer-reviewed alzhub usefulness score 61 out of 100. Alzheimer s & Dementia 2025-05-01

At baseline, Aβ+ participants showed higher CP FWf, increased white matter hyperintensity (WMH) volume, and decreased diffusion tensor image analysis along the perivascular space (DTI-ALPS). 5 key findings →

Design: cohort study Participants: 216 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Microbiota-gut-brain axis in neurodegenerative diseases: molecular mechanisms and therapeutic targets

✓ Peer-reviewed alzhub usefulness score 59 out of 100. Molecular biomedicine 2025-09-15

The microbiota-gut-brain axis (MGBA) is an intricate bidirectional communication network that links intestinal microbiota with the central nervous system (CNS) through immune, neural, endocrine, and metabolic pathways. 2 key findings →

Design: longitudinal study Evidence: moderate

Full summary, score breakdown and related studies → Original source

Curcumin and Dementia: A Systematic Review of Its Effects on Oxidative Stress and Cognitive Outcomes in Animal Models

✓ Peer-reviewed alzhub usefulness score 58 out of 100. International journal of molecular sciences 2025-07-21

Dementia is marked by progressive cognitive decline linked to oxidative stress, neuroinflammation, and synaptic dysfunction. 4 key findings →

Design: systematic review Participants: 29 Evidence: high

Full summary, score breakdown and related studies → Original source Free full text

In Vivo Cortical Microstructure: Relationships With Tauopathy and Cognitive Impairment in the Elderly

✓ Peer-reviewed alzhub usefulness score 55 out of 100. Journal of Neurochemistry 2025-08-01

Our results suggest that microstructural features derived from NODDI such as fISO might be useful adjunct markers to tau, which needs to be confirmed in longitudinal studies. 2 key findings →

Design: longitudinal study Participants: 80 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Current advances and unmet needs in Alzheimer's disease trials for individuals with Down syndrome: Navigating new therapeutic frontiers

✓ Peer-reviewed alzhub usefulness score 55 out of 100. Alzheimer s & Dementia 2025-06-01

Individuals with Down syndrome (DS) have a genetically determined form of Alzheimer's disease (AD) due to the amyloid precursor protein (APP) gene dose effect. 1 key finding →

Design: longitudinal study Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Synaptic markers are associated with cognitive decline after accounting for amyloid burden among an at-risk Alzheimer’s disease cohort

✓ Peer-reviewed alzhub usefulness score 54 out of 100. Scientific Reports 2025-06-03

Amyloid burden impacts cognitive decline in the pre-dementia stages of Alzheimer's disease (AD), but there remains significant variability in cognitive trajectories that may be explainable by markers of synaptic function and neurodegeneration. 2 key findings →

Design: longitudinal study Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Investigating neuropathological correlates of hyperactive and psychotic symptoms in dementia: a systematic review

✓ Peer-reviewed alzhub usefulness score 53 out of 100. Frontiers in dementia 2025-01-29

This systematic review aims to elucidate the neuropathological basis of the HIDA and psychosis domains, exploring whether distinct proteinopathies and neural circuit dysfunctions are associated with these symptoms. 4 key findings →

Design: systematic review Evidence: high

Full summary, score breakdown and related studies → Original source Free full text

Comprehensive metabolomics profiling reveals novel biomarkers and pathways for early detection of Alzheimer’s disease

✓ Peer-reviewed alzhub usefulness score 51 out of 100. Brain Communications 2025-01-01

Clinical Dementia Rating-Global scores (1.44 ± 0.65 versus 0.24 ± 0.25; P < 0.0001) and Patient Health Questionnaire-9 scores (4.88 ± 4.21 versus 0.20 ± 0.50; P < 0.0001) were higher than controls. 4 key findings →

Design: cross-sectional Participants: 25 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Physical and Cognitive Activities and Trajectories of AD Neuroimaging Biomarkers

✓ Peer-reviewed alzhub usefulness score 50 out of 100. Neurology 2025-12-02

= 0.038) over time. Physical activity was associated with less synaptic dysfunction and cognitive activity with less synaptic dysfunction and lower amyloid burden over time, albeit effect sizes were small. 2 key findings →

Design: longitudinal study Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

The Multinutrient Fortasyn Connect Influences Gut Microbiota and Intestinal Function in Early Alzheimer's Disease

✓ Peer-reviewed alzhub usefulness score 50 out of 100. Aging and disease 2025-11-13

Nutritional supplementation is emerging as a promising strategy to support clinical management of early Alzheimer's disease (AD), partly through modulation of the intestinal microbiome via the microbiota-gut-brain axis. 1 key finding →

Participants: 22 Evidence: low

Full summary, score breakdown and related studies → Original source

Polyphenols, Alkaloids, and Terpenoids Against Neurodegeneration: Evaluating the Neuroprotective Effects of Phytocompounds Through a Comprehensive Review of the Current Evidence

✓ Peer-reviewed alzhub usefulness score 49 out of 100. Metabolites 2025-02-13

They remain a significant focus of scientific and clinical interest due to their increasing medical and social importance. 2 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Detecting amyloid and tau pathology in Parkinson’s disease, 4R-tauopathies and control subjects with plasma pTau217

✓ Peer-reviewed alzhub usefulness score 48 out of 100. Frontiers in Neurology 2025-08-15

Plasma pTau217 levels serve as a scalable, non-invasive marker of AD-pathology across Lewy body diseases, PSP/CBS, and MCI/CU populations. 2 key findings →

Participants: 18 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Pathological mechanisms and treatment progression of Alzheimer’s disease

✓ Peer-reviewed alzhub usefulness score 47 out of 100. European journal of medical research 2025-07-14

Alzheimer's disease (AD) represents the most prevalent neurodegenerative disorder and leading cause of dementia worldwide, with its incidence rising dramatically in aging populations. 1 key finding →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

↑ Change the filters

Where “Free full text” comes from

Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read

How the 0–100 score works — and why some entries are capped

This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.

  • Journal tier up to 10 pts
  • Journal's citation record up to 4 pts
  • Study design up to 12 pts
  • Strength of evidence up to 5 pts
  • Peer-review validation up to 10 pts
  • How recent up to 5 pts
  • Sample size up to 4 pts
  • Effect reported up to 3 pts
  • Studied in people up to 3 pts
  • Randomised / blinded up to 2 pts
  • Times cited up to 7 pts
  • Citations per year up to 5 pts
  • Impact for its field and year up to 6 pts
  • Cited by studies here up to 6 pts
  • Still being cited up to 4 pts
  • Senior author's track record up to 4 pts
  • Institution's track record up to 3 pts
  • Multi-centre collaboration up to 3 pts
  • Indexed in PubMed up to 2 pts
  • Free to read up to 2 pts

Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.

Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.

We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.

The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.

See the whole rubric drawn out → — four charts covering all 27,780 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.

What this library is — and isn't

This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,780 records, built mostly from automated pulls of Europe PMC (61.1% of the library) and OpenAlex (18.3%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.

1,034 records (3.7% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.

See the full, machine-readable breakdown of this library's coverage →

Newest studies, as a dated timeline →    Atom feed